`Karen E. Keller
`300 Delaware Avenue, Suite 1120
`Wilmington, DE 19801
`(302) 298‐0700
`(302) 298‐0702 ‐ Direct
`kkeller@shawkeller.com
`
`
`
`
`
`January 29, 2016
`
`
`
`
`Cubist Pharmaceuticals, Inc. v. Fresenius Kabi USA, LLC,
`C.A. No. 14-914-GMS
`
`
`
`
`
`
`
`
`
`
`
`
`
`BY CM/ECF
`The Honorable Gregory M. Sleet
`United States District Court
`For the District of Delaware
`844 North King Street
`Wilmington, DE 19801
`
`
`Re:
`
`
`Dear Judge Sleet:
`
`
`We write on behalf of all parties in the civil action Cubist Pharms., Inc. v.
`Fresenius Kabi USA, LLC, C.A. No. 14-914 -GMS (the “Fresenius action”).
`
`
`As the Court is no doubt aware, the U.S. Court of Appeals for the Federal Circuit
`has affirmed the Court’s judgment of patent invalidity in Cubist Pharms., Inc. v. Hospira,
`Inc., C.A. No. 12-367-GMS (the “Hospira action”), and denied Cubist’s petition for
`further review of that affirmance. Today, the Federal Circuit issued its mandate. The
`Hospira and Fresenius actions involve the same patents and claims.
`
`In accord with their stipulation, D.I. 78, the parties to the Fresenius action
`respectfully request immediate entry of the attached Consent Judgment, which dismisses
`the action in its entirety with prejudice.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/s/ Karen E. Keller
`
`Karen E. Keller (No. 4489)
`
`Counsel of Record (via e-mail)
`
`
`
`
`Enclosure
`
`cc:
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,